Esperion Therapeutics, Inc.
US ˙ NasdaqGM ˙ US29664W1053

SecurityESPR / Esperion Therapeutics, Inc.
InstitutionTocqueville Asset Management L.p.
Latest Disclosed Ownership87,000 shares
Latest Disclosed Value $ 238,380
Tocqueville Asset Management L.p. reports 18.69% decrease in ownership of ESPR / Esperion Therapeutics, Inc.

On May 12, 2026 - Tocqueville Asset Management L.p. filed a 13F-HR form disclosing ownership of 87,000 shares of Esperion Therapeutics, Inc. (US:ESPR) valued at $238,380 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 107,000 shares of Esperion Therapeutics, Inc.. This represents a change in shares of -18.69% during the quarter. The current value of the position is $272,310 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F ESPERION THERAPEUTICS INC NE COM 29664W105 87,000 -20,000 -18.69 238 -39.75 0.0035
2026-02-12 2025-12-31 13F ESPERION THERAPEUTICS INC NE COM 29664W105 107,000 16,000 17.58 396 63.90 0.0058
2025-11-13 2025-09-30 13F ESPERION THERAPEUTICS INC NE COM 29664W105 91,000 27,500 43.31 241 288.71 0.0035
2025-08-12 2025-06-30 13F ESPERION THERAPEUTICS INC NE COM 29664W105 63,500 -1,500 -2.31 63 -33.33 0.0010
2025-05-13 2025-03-31 13F ESPERION THERAPEUTICS INC NE COM 29664W105 65,000 -5,000 -7.14 94 -39.61 0.0015
2025-02-10 2024-12-31 13F ESPERION THERAPEUTICS INC NE COM 29664W105 70,000 -2,500 -3.45 154 29.41 0.0024
2024-11-08 2024-09-30 13F ESPERION THERAPEUTICS INC NE COM 29664W105 72,500 -5,000 -6.45 120 -30.81 0.0019
2024-08-12 2024-06-30 13F ESPERION THERAPEUTICS INC NE COM 29664W105 77,500 37,750 94.97 172 62.26 0.0028
2024-05-09 2024-03-31 13F ESPERION THERAPEUTICS INC NE COM 29664W105 39,750 39,750 107 0.0017
2020-11-16 2020-09-30 13F ESPERION THERAPEUTICS INC NE COM 29664W105 0 -5,500 -100.00 0 -100.00
2020-08-12 2020-06-30 13F ESPERION THERAPEUTICS INC NE COM 29664W105 5,500 5,500 282 0.0059
2020-05-15 2020-03-31 13F Esperion Therapeutics COM 29664W105 0 -5,500 -100.00 0 -100.00
2020-01-14 2019-12-31 13F Esperion Therapeutics COM 29664W105 5,500 5,500 328 0.0048
2018-08-13 2018-06-30 13F Esperion Therapeutics COM 29664W105 0 -2,975 -100.00 0 -100.00
2018-05-14 2018-03-31 13F Esperion Therapeutics COM 29664W105 2,975 2,975 215 0.0027
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.